For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

Shares of pharmaceutical companies dropped early Monday after President Donald Trump said he would lower the cost of medicines for Americans by between 30% and 80%. Shares of major U.S. drugmakers Eli ...

Empower Pharmacy markets itself as a well-meaning rival to Big Pharma - one that seeks to democratize medicine by making ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Potential lower prices risk not only bringing down revenue from medicines already on the market, but also hurting the ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Dan Dischner; Vice President - Corporate Communications; Amphastar Pharmaceuticals Inc. William Peters; Chief Financial Officer, Executive Vice President - Finance, ...

Operator: Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants ...